Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.83 |
| ▸ | GAA | P10253 | 4/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.78 |
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | NSD2 | O96028 | 1/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | GFER | P55789 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3174973 | 0.93 | KMT2A (0.73) | KMT2AGAAALDH1A1MEN1NSD2 | |
| SCHEMBL3174969 | 0.93 | KMT2A (0.73) | KMT2AGAAALDH1A1MEN1NSD2 | |
| SCHEMBL18686969 | 0.83 | KMT2A (0.61) | KMT2AGAAALDH1A1MEN1NSD2 | |
| SCHEMBL17304291 | 0.83 | KMT2A (0.61) | KMT2AGAAALDH1A1MEN1NSD2 | |
| SCHEMBL3165809 | 0.81 | KMT2A (0.79) | KMT2AGAAALDH1A1MEN1NSD2 | |
| SCHEMBL3181773 | 0.76 | KMT2A (0.52) | KMT2AGAAALDH1A1MEN1NSD2 | |
| SCHEMBL3175319 | 0.74 | CXCR4 (0.55) | KMT2AGAAALDH1A1MEN1NSD2 | |
| SCHEMBL18716022 | 0.71 | NPC1 (0.49) | KMT2AGAAALDH1A1MEN1NSD2 | |
| SCHEMBL7266585 | 0.66 | KMT2A (0.43) | KMT2AGAAALDH1A1MEN1NSD2 | |
| SCHEMBL8636091 | 0.65 | ALDH1A1 (0.50) | KMT2AGAAALDH1A1MEN1NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022769-A1 | NOVEL POLYNITROGENATED SYSTEMS AS ANTI-HIV AGENTS | INSTITUT QUIMIC DE SARRIA CETS (ES) | 2010-01-28 | — | — | US | claimed |
| EP-2100890-A1 | NOVEL POLYNITROGENATED SYSTEMS AS ANTI-HIV AGENTS | Institut Quimic De Sarria Cets (ES) | 2009-09-16 | — | — | EP | claimed |
| US-20100022769-A1 | NOVEL POLYNITROGENATED SYSTEMS AS ANTI-HIV AGENTS | INSTITUT QUIMIC DE SARRIA CETS (ES) | 2010-01-28 | — | — | US | disclosed |
| EP-2100890-A1 | NOVEL POLYNITROGENATED SYSTEMS AS ANTI-HIV AGENTS | Institut Quimic De Sarria Cets (ES) | 2009-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022769-A1 | NOVEL POLYNITROGENATED SYSTEMS AS ANTI-HIV AGENTS | MSR1, CCR5, CD4 | KMT2A 2638/4885GAA 4133/4885ALDH1A1 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.